PureHealth reported 75% UAE hospital occupancy. Burjeel reported 69% on a 1,784-bed network. Every private-hospital deal in the region now negotiates against a public benchmark.

In the first week of August 2026 the two largest UAE-listed hospital operators disclosed six-month results within days of each other, and the Saudi-listed multi-hospital group followed on the same interim clock. Read the three sets of primary disclosures together and the negotiating floor for every private hospital and clinic deal in the region has moved. Listed-operator occupancy and margin are the only public pricing evidence in this sector; where a private target quotes a multiple, the listed comps are what the multiple has to justify itself against.
WHAT PUREHEALTH DISCLOSED PureHealth Holding PJSC reported group revenue of AED 14.9 billion for H1 2026, up 9% year on year, with EBITDA of AED 2.9 billion, up 24%, and net profit of AED 1.2 billion, up 20% (PureHealth H1 2026 release, 31 July 2026). The number every private-hospital deal in the UAE now negotiates against is the operator's disclosed UAE hospital bed occupancy of 75% for the half. Outpatient volumes were up 7% and inpatient volumes up 10%, insured membership stood at 3.4 million, and international operations contributed 33% of group revenue. The 75% figure is the H1 2026 UAE reference; any private target quoting a premium multiple has to reconcile that premium against a listed comp already running at three-quarters utilisation.
WHAT BURJEEL DISCLOSED, AND WHY THE ONE-OFFS MATTER Burjeel Holdings PLC (ADX: BURJEEL) reported group revenue of AED 2,794 million for H1 2026, up 4.4% year on year, on the same ADX cycle five days later (Burjeel H1 2026 press release, ADX-hosted primary, 5 August 2026). EBITDA ex-one-offs rose 24.6% to AED 517 million and net profit ex-one-offs rose 97.4% to AED 227 million. Operating cash flow climbed 76.8% to AED 405 million, and net leverage remained at 1.8x after the completion on 1 July 2026 of a US$500 million sukuk under the group's US$1.5 billion programme. Bed occupancy averaged 69% across a 1,784-bed network, and 3.7 million patient visits were 9.9% ahead of H1 2025. On a normalised basis excluding the effect of the Unified Pricing Policy the group's H1 revenue growth was 9.1%, not 4.4% — a distinction a buyer needs in the room, because the reported 4.4% is a policy-adjusted print, not an underlying-growth print. The Hospitals segment, at 89% of group revenue and an EBITDA margin of 22.5%, is the read for a hospital-target comp; the Medical Centres segment, at AED 248 million and an EBITDA margin that expanded on 56.2% EBITDA growth, is the read for a clinic-target comp.
MOUWASAT AND THE KSA DISCLOSURE ASYMMETRY On the Saudi Exchange, Mouwasat Medical Services Company (Tadawul: 4002) reported H1 2026 revenue of SAR 1,710 million, up 9.58%, and net profit of SAR 412.4 million, up 7.39%, on its interim disclosure (Saudi Exchange primary interim disclosure, Mouwasat 4002). Operating income was SAR 410.9 million, marginally down 0.4%. The Yanbu Industrial City hospital transferred SAR 407.9 million from construction in progress into property and equipment following commencement of operations on 1 February 2026 — capacity that is now on the balance sheet but not yet in the earnings run-rate. What is not in the interim disclosure is bed occupancy. Saudi Exchange interim rules do not require it, and Mouwasat does not volunteer it. For a KSA hospital-target valuation, the peer arithmetic has to be built off revenue growth and margin — not utilisation — and any private-market benchmark that leans on an assumed occupancy figure will not survive a data-room challenge without a primary anchor.
WHERE THE COMPS ACTUALLY PRICE A DEAL For a private-hospital target in the UAE, PureHealth's 75% occupancy is the ceiling to justify a premium against and Burjeel's 69% is the floor to justify a discount against. A target running above 75% at scale should be reflected in the multiple; a target running below 69% either has a capacity story or a demand story, and the buyer's diligence needs to identify which. The margin dispersion is wider than the occupancy dispersion — PureHealth reports at group EBITDA level, Burjeel reports Hospitals-segment margin at 22.5% — and a comp is only as good as the segmentation that produced it. For a KSA target, revenue growth in the high single digits and net-margin trajectory read against Mouwasat's SAR 1,710m / SAR 412.4m arithmetic is the arithmetic; imported UAE-style occupancy comps do not translate. In both markets, one-off items — post-acquisition gains, partnership exits, sukuk-issuance costs — need to be stripped consistently across peer and target, or the earnings normalisation quietly does the buyer's or seller's work for them.
The Monday work is finite. Pull PureHealth's, Burjeel's and Mouwasat's H1 2026 primaries and lay the target's H1 alongside on a like-for-like basis, matched by segment. Reconcile the earnings normalisation — one-offs, UPP effect, sukuk finance costs — so buyer and seller are on the same base before a multiple is discussed. For a KSA target, source the utilisation comp from private benchmarks that will withstand challenge, or price the deal without one. That valuation and diligence work is where our business valuation practice begins.